Resumen de Quimioprevención del cáncer colorrectal con inhibidores de la ciclo-oxigenasa-2
Ángel Plaza Martínez, José F. Noguera Aguilar, José Miguel Morón Canis, Eduardo Ortiz Monzón
Colorectal cancer supposes an important health problem in developed countries because of its frequency, its mortality and its costs. In an attempt to improve the global results of its treatment, it has been introduced a new strategy, chemoprevention. It has been evaluated the capacity to prevent colon cancer from many chemical agents, but it seems that the nonsteroidal anti-inflammatory drugs and, more particularly the selective inhibitors of cyclo-oxygenase-2 enzyme, are the most promising agents. Multiple studies, first epidemiologic, later in animal models of carcinogenesis and finally clinical trials, fundamentally in subgroups of patients genetically predisposed to suffer from colon cancer, support the chemiopreventive capacity of these drugs. However, there are still left to elucidate the ideal drug, the drug dosage, the treatment duration and, above all, the place that they would occupy in the general strategy of the fight against colorectal cancer. In this present work, we try to give a global vision of the problem and of the knowledge and the present lines of work
